AKBA Jan 2025 1.500 call
| Previous Close | 0.1800 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.1800 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 79 |
Simply Wall St.Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- PR Newswire
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m. ET.
